Body composition change in people living with HIV after transition antiretroviral therapy from TDF/FTC/EFV to TDF/3TC/DTG

Phase 1

• Conditions: Body composition in people living with HIV after changing ARV from TDF/FTC/EFV to TDF/3TC/DTG; Body composition, metabolic, HIV, TEEVIR, Acriptega

• Registration Number: TCTR20240404003
• Lead Sponsor: Ramathibodi Hospital foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-04
• Last Update Posted: 19 August 2024
• Study Completion: 2025-01-30

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

1. Patient living with HIV who can come follow up at Ramathibodi Hospital
2. Prescribed TDF/FTC/EFV at least 6 mo. prior include in this study
3. Age > 20 yr
4. HIV viral load <200 copies/mL
5. CD4 level > 200 cells/mL
6. Accept to join the project by signing the consent

Exclusion Criteria

1. Follow up less than 2 times after join the project
2. Got pregnant during join the project
3. Got infected by opportunistic infection during join the project
4. Not viable for measured body composition using bioelectrical impedance analysis machine

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body composition change 8 month Bioelectrical impedance analysis

Secondary Outcome Measures

Name	Time	Method
Metabolic profile 8 month Fasting blood sugar, Lipid profile